[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519202":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":23,"studyPopulation":13,"armGroups":24,"interventions":35,"overallOfficials":13,"centralContacts":40,"locations":13,"responsibleParty":46,"collaborators":48,"id":51,"slug":13,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":13,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":13,"studyType":63,"phases":64,"briefSummary":55,"conditions":66,"keywords":13,"overallStatus":68,"whyStopped":13,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":13},{"fullName":5,"class":6},"StemCyte International, Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"safety-TEAE","Frequency and incidence of treatment-emergent adverse events (TEAEs).","From screening to 48 weeks",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"DOUBLE",[21,22],"PARTICIPANT","INVESTIGATOR","This is a phase II study to evaluate the safety and efficacy in hUCB treatment on the patients with acute ischemic stroke (AIS).",[25,31],{"label":26,"type":27,"description":28,"interventionNames":29},"A group: hUCB treatment","EXPERIMENTAL","Human cord blood infusion",[30],"Biological: hUCB",{"label":32,"type":33,"description":34,"interventionNames":13},"B group: Placebo treatment","NO_INTERVENTION","Placebo infusion",[36],{"type":37,"name":38,"description":38,"armGroupLabels":39,"otherNames":13},"BIOLOGICAL","hUCB",[26],[41],{"name":42,"role":43,"phone":44,"phoneExt":13,"email":45},"Ying Chieh Bobo Chen, PhD","CONTACT","02-26013013 Ext809","bobo.chen@stemcyte.com.tw",{"type":47,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[49],{"name":50,"class":6},"StemCyte Taiwan Co., Ltd.","100519202",false,"NCT06040476","Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)","A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke","Inclusion Criteria:\n\n* Male or female subject ≥18 and ≤80 years of age.\n* Subject with a confirmed diagnosis of AIS and hemiplegia\n\nExclusion Criteria:\n\n* Subject with known immune disease, immunodeficiency, or receives immunosuppressive therapy\u002Fimmunomodulators within 4 weeks or 5 half-lives prior to screening, whichever is longer.","ALL","18 Years","80 Years",{"count":61,"type":62},39,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2",[67],"Acute Ischemic Stroke","NOT_YET_RECRUITING","2025-02-25",{"date":71,"type":72},"2025-02-27","ACTUAL",{"date":74,"type":62},"2025-09",{"date":76,"type":62},"2028-08",{"name":78,"class":6},"StemCyte, Inc."]